ROBERT E. SLAYTON, M.D.; CHARLES PERLIA, M.D.; JOHN SHOWEL, M.D.; THOMAS HOELTGEN, M.D.; JANET WOLTER, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: We take strong issue with a recent letter from A. W. Hopefl (Ann Intern Med 82:722, 1975) suggesting that mithramycin be reserved for the hypercalcemic patient who has not responded to "other more benign therapy" and used only by those experienced in chemotherapy. We have found mithramycin more reliable, yet no more toxic than other hypercalcemic agents, and strongly encourage its use early in the treatment of hypercalcemia. It is quite clear that the risks of hypercalcemia are greater than the risks of mithramycin if attention is paid to dose and frequency of administration.
Learn more about subscription options.
Register Now for a free account.
SLAYTON RE, PERLIA C, SHOWEL J, HOELTGEN T, WOLTER J. Mithramycin for Hypercalcemia. Ann Intern Med. 1975;83:288. doi: 10.7326/0003-4819-83-2-288_1
Download citation file:
Published: Ann Intern Med. 1975;83(2):288.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only